Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

• Status: Terminated
• Trial end date: 2017-11-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.

• Clinical diagnosis of Parkinson's disease.

• Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion Criteria:

• Female of childbearing potential

• History or presence of atypical Parkinsonian syndrome.

• History of surgical intervention for Parkinson's disease.

• Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

• Any condition possibly affecting drug absorption.

• Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.